Company Focus

Lamina’s lead product lamina.ONE consists of a combined advanced therapy medicinal product (cATMP) composed of two compartments.

The medical device (MD) compartment is a thin bioresorbable nanofibrous wound dressing equipped with a bone mineral, hydroxyapatite. The ATMP consists of a hydrogel-stem cells mixture for cartilage regeneration. It is intended for subtle subchondral bone regeneration in order to stabilize the newly-regenerated cartilage. Thus, lamina.ONE is offering a hybrid therapeutic effect by repairing both articular cartilage and subchondral bone for a full recovery of the articular joint. It will prevent the patient from having to undergo knee replacement surgery over time.

Lamina.ONE’s technology offers a single intervention compared to total knee replacements (TKA) usually accompanied by revision surgeries. Our solution consists of a mini-invasive protocol, with a lower risk of complications, resulting in a shorter recovery time and higher success rate.

Our innovative technology provides a localized solution adaptable to the stage of osetoarthritis of the patient initiating a radically new treatment approach to bone and cartilage regeneration and other unsolved musculoskeletal problems associated with age.

Lamina.ONE’s technolgy could offer the delivery of multiple therapeutic agents in combination with different cells to accelerate tissue regeneration for multiple applications such as periodontal and maxillofacial lesions.

With our manufactured Lamina.ONE kit, we are moving to clinical trial phase I/IIa for isolated osteochondral lesions in the knee (first quarter of 2023).